Pfizer Inc (PFE) 33.97 $PFE 3 Little-Known Stocks I'm

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Pfizer Inc (PFE) 33.97 $PFE

3 Little-Known Stocks I'm Glad I Bought
Todd Campbell, The Motley Fool - Motley Fool - Sun Mar 08, 12:04PM CDT
Source: Flickr user stockmonkeys.com. Investing in clinical-stage biotech stocks isn't for the faint of heart. The industry's jaw-dropping pops and drops can be so dramatic as to suit these stocks only the most speculative portion of an investor's...
JNJ: 100.11 (-2.41), INSY: 57.69 (+0.08), PTLA: 41.72 (-0.13), PFE: 33.97 (-0.50), OPHT: 53.19 (-0.29), BMY: 65.12 (-0.93), REGN: 422.13 (-6.82), NVS: 97.46 (-1.49)

Did Pfizer Inc. Just Gut Its Chances of Finding New Blockbusters?
Todd Campbell, The Motley Fool - Motley Fool - Sun Mar 08, 8:59AM CDT
Source: Pfizer, via Facebook. Pfizer Inc.  and other big drugmakers have a problem on their hands. Facing a steady stream of patent expirations on top-selling medicines, they're caught in a tug-of-war between developing next-generation therapies...
PFE: 33.97 (-0.50), MRK: 56.84 (-1.14), HSP: 87.90 (+0.05)

2 Tiny Biotechs That Could Have Blockbuster Opportunity
Todd Campbell and Michael Douglass, The Motley Fool - Motley Fool - Sat Mar 07, 9:11AM CST
Smaller health care stocks are not for the faint of heart. When it comes to developing and testing new drugs, the success rate is tiny but the rewards can be huge. How can the risk-tolerant Fool spot the next Amgen or Biogen ? This health care...
JNJ: 100.11 (-2.41), BIIB: 417.63 (-7.98), PTLA: 41.72 (-0.13), PFE: 33.97 (-0.50), OPHT: 53.19 (-0.29), AMGN: 154.88 (-4.72), BMY: 65.12 (-0.93), NVS: 97.46 (-1.49), CELG: 118.03 (-2.68)

6.86% Advantage To 5 Dow Highest Yield, Lowest Price, March Dogs With Coca-Cola
Fredrik Arnold - at Seeking Alpha - Sat Mar 07, 7:28AM CST

KO: 41.52 (-0.88), T: 33.48 (-0.52), GE: 25.42 (-0.40), PFE: 33.97 (-0.50), MRK: 56.84 (-1.14), XOM: 85.63 (-1.11), MCD: 97.13 (-1.98), CAT: 80.06 (-1.45), CVX: 103.55 (-1.18), VZ: 48.29 (-0.63)

12.88% Edge To 5 Dow Highest Yield, Lowest Price, March Dogs With Procter & Gamble
Fredrik Arnold - at Seeking Alpha - Sat Mar 07, 5:59AM CST

T: 33.48 (-0.52), GE: 25.42 (-0.40), PFE: 33.97 (-0.50), MRK: 56.84 (-1.14), XOM: 85.63 (-1.11), MCD: 97.13 (-1.98), PG: 82.66 (-1.97), CAT: 80.06 (-1.45), CVX: 103.55 (-1.18), VZ: 48.29 (-0.63)

Top 10 Dow Dividend Dogs Disport 8.21% To 16.12% Upsides In March
Fredrik Arnold - at Seeking Alpha - Sat Mar 07, 4:15AM CST

KO: 41.52 (-0.88), GE: 25.42 (-0.40), AXP: 80.31 (-0.84), UTX: 119.43 (-1.36), PFE: 33.97 (-0.50), INTC: 33.19 (-0.54), T: 33.48 (-0.52), JNJ: 100.11 (-2.41), JPM: 60.89 (-1.11), MRK: 56.84 (-1.14), MCD: 97.13 (-1.98), PG: 82.66 (-1.97), CAT: 80.06 (-1.45), CVX: 103.55 (-1.18), MSFT: 42.36 (-0.75), VZ: 48.29 (-0.63)

Seeking Alpha's Biotech Weekly: AbbVie - Pharmacyclitics, Orexigen Confusion, And More
SA Editor Mike Taylor - at Seeking Alpha - Fri Mar 06, 3:00PM CST
Every Friday, Seeking Alpha's Biotech Weekly highlights the editors' picks of the week's Seeking Alpha analysis, as well as a review of the top Breaking News stories. See something here that deserves further analysis? We are always looking for new...
PCYC: 254.56 (+0.34), MDT: 76.48 (-2.02), ARWR: 7.75 (-0.19), SPHS: 0.70 (-0.03), BSX: 16.56 (-0.41), MDVN: 126.55 (-0.53), JNJ: 100.11 (-2.41), AAC: 29.30 (-2.80), ABBV: 55.64 (-1.22), SNY: 47.42 (-0.94), SMMT: 10.29 (+0.10), ARNA: 4.32 (+0.09), XLRN: 40.55 (-0.79), MNK: 121.33 (-0.37), AQXP: 10.49 (+0.43), PFE: 33.97 (-0.50), AMGN: 154.88 (-4.72), GSK: 46.73 (-0.87), BMY: 65.12 (-0.93), MNKD: 5.47 (-0.26), CELG: 118.03 (-2.68), OREX: 7.10 (-0.91), PODD: 32.24 (+0.26), GERN: 3.50 (-0.28), TEVA: 56.40 (-0.11), TCON: 17.57 (+0.36), NVS: 97.46 (-1.49)

3 Big Pharma Stocks to Buy in March
Brian Orelli, Dan Caplinger, and Todd Campbell, The Motley Fool - Motley Fool - Fri Mar 06, 2:16PM CST
With the Ides of March approaching, we asked our team of Fool.com healthcare contributors to identify big pharma stocks that look like good picks this month. Read on to see why Dan, Todd, and Brian think  Pfizer , Bristol-Myers Squibb , and ...
JNJ: 100.11 (-2.41), PFE: 33.97 (-0.50), BMY: 65.12 (-0.93)

Regeneron Jumps Ahead In $10 Billion Race For Next Generation Cardio Drugs
Cheryl Swanson - at Seeking Alpha - Fri Mar 06, 1:35PM CST

PFE: 33.97 (-0.50), AMGN: 154.88 (-4.72), SNY: 47.42 (-0.94), REGN: 422.13 (-6.82)

3 Prevailing Myths About Dividend Stocks
Motley Fool Staff - Motley Fool - Fri Mar 06, 7:15AM CST
Are higher dividend yields always better than low ones? Are dividend stocks always safe? And are all dividends taxed the same? Dividend investing can be one of the most certain paths toward long-term wealth, but it's important to separate fact from...
GE: 25.42 (-0.40), PFE: 33.97 (-0.50), VGR: 22.50 (-0.26)

Pfizer's Strong FCF Means Big Dividend Growth
Josh Arnold - at Seeking Alpha - Fri Mar 06, 1:44AM CST

PFE: 33.97 (-0.50)

AbbVie Stock Slides On Pricey Pharmacyclics Deal
at Investor's Business Daily - Thu Mar 05, 3:56PM CST
Big pharma AbbVie's $21 billion deal to acquire hot biotech Pharmacyclics was met with widespread skepticism by AbbVie investors Thursday, sending AbbVie's stock falling 5.7% Thursday. AbbVie (ABBV) announced the cash-and-stock acquisition late...
JNJ: 100.11 (-2.41), PCYC: 254.56 (+0.34), PFE: 33.97 (-0.50), AMGN: 154.88 (-4.72), ABBV: 55.64 (-1.22), NVS: 97.46 (-1.49)

Pfizer's Prevenar Cleared in the EU for New Indication - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Mar 05, 3:30PM CST
Pfizer Inc (PFE) announced that Prevenar 13 was approved in the EU for a new indication.
JNJ: 100.11 (-2.41), MRK: 56.84 (-1.14), PFE: 33.97 (-0.50), GSK: 46.73 (-0.87)

Stock Market News for March 05, 2015 - Market News
Zacks Equity Research - Zacks Investment Research - Thu Mar 05, 9:10AM CST
Markets ended in the red for the second consecutive day, handing the Dow and S&P 500 their worst closing levels since Feb 19
KO: 41.52 (-0.88), MMM: 164.36 (-3.21), GE: 25.42 (-0.40), UTX: 119.43 (-1.36), PFE: 33.97 (-0.50), UNH: 112.88 (-1.91), WMT: 82.59 (-0.98), AMGN: 154.88 (-4.72), BA: 153.12 (-1.35), CELG: 118.03 (-2.68), PM: 80.05 (-1.66), ADP: 86.00 (-0.75), ABBV: 55.64 (-1.22), PG: 82.66 (-1.97)

Today's Market: Pharma Mergers And Acquisitions Impacting These Stocks
Matthew Smith - at Seeking Alpha - Thu Mar 05, 8:02AM CST

JNJ: 100.11 (-2.41), VRX: 198.71 (-5.24), PCYC: 254.56 (+0.34), PFE: 33.97 (-0.50), SLXP: 158.01 (+0.57), ABBV: 55.64 (-1.22), NVS: 97.46 (-1.49)

Merck KGaA's Q4 Net Income Flat Y/Y, Provides 2015 Outlook - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Mar 04, 9:40AM CST
Merck KGaA's (MKGAF) net income during the fourth quarter of 2014 came in at 280 million euros compared with 280.6 million euros in the year-ago period.
PFE: 33.97 (-0.50), SLXP: 158.01 (+0.57), SCMP: 15.64 (+0.49)

3 Companies That Could Unlock Shareholder Value Through a Split or Spinoff
Motley Fool Staff - Motley Fool - Wed Mar 04, 8:08AM CST
There are a number of reasons companies might consider spinning off parts of their operations. A spinoff may happen if a company's sales are sliding and it needs to raise cash. In other cases, activist investors lobby aggressively for a spinoff after...
GE: 25.42 (-0.40), PFE: 33.97 (-0.50), CMG: 658.68 (-11.81), C: 53.06 (-0.50), SYF: 31.20 (-0.76), HSP: 87.90 (+0.05), YUM: 79.16 (-1.36)

Pfizer Inc. Has a Growth Problem -- Here Are 3 Ways to Change That
Sean Williams, The Motley Fool - Motley Fool - Wed Mar 04, 7:02AM CST
Source: Pfizer, Facebook. Pfizer might be the largest pharmaceutical products company in the world by revenue, but it looks far from a force to be reckoned with at the moment. Pfizer's problems in a nutshell Like much of the big...
ISIS: 70.44 (-1.32), JAZZ: 172.12 (-2.64), AZN: 66.27 (-1.91), PFE: 33.97 (-0.50)

Pfizer's
at Investor's Business Daily - Tue Mar 03, 5:33PM CST
Pfizer's (PFE) blockbuster vaccine Prevnar 13, which shields against 13 strains of pneumococcal disease, has been approved for use in EU residents 18 and up. Shares fell 0.6% to 34.56.
PFE: 33.97 (-0.50)

Amgen: The Best Biotech Stock You Don't Own
Dan Strack - at Seeking Alpha - Tue Mar 03, 4:04PM CST

BIIB: 417.63 (-7.98), GILD: 101.81 (-1.61), PFE: 33.97 (-0.50), MRK: 56.84 (-1.14), AMGN: 154.88 (-4.72), ABBV: 55.64 (-1.22), GSK: 46.73 (-0.87), BMY: 65.12 (-0.93), HSP: 87.90 (+0.05), NVS: 97.46 (-1.49), CELG: 118.03 (-2.68)




Scroll down for more posts ▼

Top 10 Most Recent News Articles

Top 5 Most Recently Viewed Articles

Main Street Capital's Impressive Loan Portfolio Growth Report

Updated Category News Views 126

Main Street Capital's Evolving Private Loan Portfolio Main Street Capital Corporation (NYSE: MAIN) has made remarkable strides in developing its private loan portfolio. During the fourth quarter of the year, Main Street recorded a significant increase in new loan commitments amounting to $123.4 million, alongside investments totaling $108.0 million across its portfolio....

Continue Reading
Reality Based Group Joins Forces with Dave's Hot Chicken

Updated Category News Views 136

Enhancing Customer Experiences Together Reality Based Group, known for its innovative approach to improving customer experiences, is making waves in the food service industry through a new partnership with Dave's Hot Chicken. This fast-growing chain, popular for its delicious menu offerings, has recognized the value of enhancing its customer service via advanced...

Continue Reading
JMIR Maintains Leadership with Impressive Impact Gains

Updated Category News Views 5

Jumping right in, JMIR Publications is making waves in the academic world with its latest Journal Impact Factor (JIF) triumphs. If these folks were publicly traded, you'd want a piece because they are dominating the digital health research scene like no other. Emphasizing their stronghold, 12 out of their 24 journals clinched top-quartile spots this year—a feat that's...

Continue Reading
21shares Introduces Canton Network ETP for Blockchain Access

Updated Category News Views 224

21shares Unveils New Canton Network ETP 21shares, a prominent issuer of cryptocurrency exchange-traded products (ETPs), has made waves in the financial markets with the introduction of the 21shares Canton Network ETP (CANTN). This innovative offering enables investors to gain exposure to the Canton Coin, the native utility token within the Canton Network, an initiative...

Continue Reading
Market Trends Report: Economic Factors Drive Stock Movements

Updated Category News Views 359

The stock market experienced mixed results recently as investors zeroed in on critical economic indicators and job reports. Amidst ongoing geopolitical tensions, particularly in the Middle East, traders were navigating through uncertainty that impacted their portfolios. Major Indices Performances: Diverging Paths The S&P 500 dropped by 0.2%, while the Dow Jones Industrial...

Continue Reading